Review Article
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
Table 3
Efficacy results of VICTOR trial in the TNBC population.
| Variable | Overall | |
| Clinical benefit rate (CR + PR + SD ≥ 24 weeks) (%) | 10/28 (35.7) | | [18.6–55.9] | Kaplan-Meier estimate of median duration of clinical benefit (months) | 11.3 | Disease control rate (CR + PR + SD) | 15/28 (53.6%) | Kaplan-Meier estimate of median duration of response in disease control (months) | 7.4 | Kaplan-Meier estimate of median PFS (months) | 4.7 |
|
|